Vitamin B₆ in the Treatment of Tardive Dyskinesia: A Double-Blind, Placebo-Controlled, Crossover Study

Abstract

Vitamin B(6) appears to be effective in reducing symptoms of tardive dyskinesia.

Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology

“…The authors cited only one of our articles regarding treatment of tardive dyskinesia (TD). 2 Even though the authors performed a search from 1966 to 2011, they did not include 2 studies published in 2007 that could broaden the knowledge about new options for TD management. 3,4 The first deals with vitamin B 6 and the other with piracetam.…”

“…2 Even though the authors performed a search from 1966 to 2011, they did not include 2 studies published in 2007 that could broaden the knowledge about new options for TD management. 3,4 The first deals with vitamin B 6 and the other with piracetam. Both studies include large samples (50 and 40 subjects, respectively) and could be considered Class I evidence according to the authors' classification.…”

“…As the authors noted, 2 studies on vitamin B 6 and piracetam were not included in our original analysis. 3,4 The first study, a double-blind, placebo-controlled trial on vitamin B 6 treatment in 50 inpatients with schizophrenia/schizoaffective disorders, was rated Class III for no allocation concealment and a .20% (14/50) dropout rate. 3 The second study of 40 patients with schizophrenic/schizoaffective disorders who received piracetam or placebo over 4 weeks was rated Class III for the same reasons (9 dropouts).…”

“…3,4 The first study, a double-blind, placebo-controlled trial on vitamin B 6 treatment in 50 inpatients with schizophrenia/schizoaffective disorders, was rated Class III for no allocation concealment and a .20% (14/50) dropout rate. 3 The second study of 40 patients with schizophrenic/schizoaffective disorders who received piracetam or placebo over 4 weeks was rated Class III for the same reasons (9 dropouts). 4 After applying the AAN's classification scheme for rating therapeutic articles, 5 we found the data remain insufficient to support or refute use of vitamin B 6 and piracetam as TDS treatments.…”

Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology

“…The authors cited only one of our articles regarding treatment of tardive dyskinesia (TD). 2 Even though the authors performed a search from 1966 to 2011, they did not include 2 studies published in 2007 that could broaden the knowledge about new options of TD management. 3,4 The first deals with vitamin B 6 and the other with piracetam.…”